Ingredion Q1 Revenue Matches Expectations at $1.79B
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy INGR?
Reports Q1 revenue $1.79B, consensus $1.79B. "While we expected a challenging first quarter after last year's strong first quarter, results were weaker than anticipated in Food & Industrial Ingredients-U.S./CAN due to operational challenges at our Argo facility," said Jim Zallie, chairman, president and CEO of Ingredion. "At the same time, performance in our Texture & Healthful Solutions and Food & Industrial Ingredients-LATAM segments were in line with our expectations despite an increasingly uncertain macroeconomic environment."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INGR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INGR
Wall Street analysts forecast INGR stock price to rise
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 107.360
Low
119.00
Averages
125.50
High
136.00
Current: 107.360
Low
119.00
Averages
125.50
High
136.00
About INGR
Ingredion Incorporated is a global ingredient solutions provider serving customers in nearly 120 countries. The Company turns grains, fruits, vegetables and other plant-based materials into value-added ingredient solutions for the food, beverage, animal nutrition, brewing and industrial markets. Its segments include Texture & Healthful Solutions (T&HS), Food & Industrial Ingredients - Latin America (F&II - LATAM) and Food & Industrial Ingredients - U.S./Canada (F&II - U.S./Canada). Its product lines include starches and sweeteners, animal feed products and edible corn oil. Its starch-based products include both food-grade and industrial starches, as well as biomaterials and non-GMO (genetically modified organism) products. Its sweetener products include glucose syrups, high maltose syrups, high fructose corn syrup, caramel color, dextrose, polyols, maltodextrins, glucose and syrup solids, high-intensity sweeteners, and various non-GMO products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ingredion Q1 Earnings Miss Expectations with EPS Guidance Adjusted
- Earnings Performance: Ingredion's Q1 non-GAAP EPS of $2.34 missed expectations by $0.13, indicating pressure on profitability that could undermine investor confidence and stock performance.
- Revenue Decline: The company reported revenue of $1.79 billion, a slight year-over-year decrease of 1.1%, which, while in line with expectations, suggests a lack of sales growth that may impact future market competitiveness.
- Guidance Adjustment: Ingredion adjusted its full-year EPS guidance to a range of $9.60 to $10.30, with adjusted EPS guidance set at $10.45 to $11.15, falling short of the $11.33 consensus, reflecting a cautious outlook on future performance.
- Stock Reaction: Following the earnings report, Ingredion's shares fell by 4%, indicating market concerns regarding the company's performance and future prospects, which may lead investors to reassess their investment strategies.
See More
Ingredion Set to Announce Q1 Earnings on May 5
- Earnings Announcement Date: Ingredion (INGR) is scheduled to announce its Q1 2023 earnings on May 5 before market open, with consensus EPS estimate at $2.47, reflecting a 16.8% year-over-year decline, which could negatively impact investor sentiment.
- Revenue Decline Expected: The anticipated revenue for Q1 is $1.79 billion, down 1.1% year-over-year, indicating challenges the company faces in the current economic environment, potentially affecting its future market performance.
- Historical Performance Review: Over the past two years, Ingredion has only beaten EPS estimates 75% of the time and has never exceeded revenue estimates, highlighting ongoing pressures on the company's profitability and revenue growth.
- Management Change: Jason Payant was appointed interim CFO effective April 1, a change that may influence the company's financial strategy and investor confidence during a critical period of transformation and growth.
See More
Sensient Technologies Set for Growth as Shift to Natural Dyes Accelerates
- Market Transformation Opportunity: According to UBS, U.S. food producers and grocers are transitioning from synthetic dyes to natural colorants, which is expected to create significant growth opportunities for Sensient Technologies, with analyst Joshua Spector noting this shift will act as a positive catalyst for the company's stock.
- Price Target Increase: UBS initiated coverage with a buy rating on Sensient, setting a price target of $115, implying a 33% upside from Tuesday's close, reflecting confidence in the company's future growth potential.
- Sales Growth Expectations: By 2030, Sensient's color group sales are projected to increase by over 200% due to the growing adoption of natural food colorings, significantly enhancing the company's market share and profitability, particularly in North America.
- Analyst Consensus: Among the three analysts covering Sensient, two have assigned strong buy or buy ratings, indicating a general optimism about the company's future performance, despite its shares having fallen nearly 3% year-to-date.
See More
Jim Cramer's Trust Increases Stake in Cardinal Health
- Increased Stake: Jim Cramer's Charitable Trust purchased 25 shares of Cardinal Health at approximately $210, raising its total holdings to 475 shares and increasing its portfolio weighting from 2.5% to 2.6%, reflecting confidence in the company.
- Market Reaction: Cardinal Health's stock has pulled back about 9% since the onset of the conflict with Iran; however, the company is expected to see earnings per share grow approximately 25% in the current fiscal year, indicating strong profitability amid market volatility.
- Product Growth: Sales of GLP-1 medications have provided a significant tailwind to Cardinal's Pharmaceutical and Specialty Solutions business, contributing 6 percentage points to revenue growth in the most recent quarter, further solidifying its market position.
- Board Changes: The sudden retirement of Chairman Gregory Kenny, replaced by current director Patricia Hemingway Hall, may unsettle investors; however, the company clarified that this decision was not related to operational disagreements and maintains confidence in its future financial outlook.
See More
Ingredion Appoints Interim CFO Jason Payantas Effective April 2026
- Executive Change: Ingredion announced that Jason Payantas will serve as interim Chief Financial Officer starting April 1, 2026, succeeding James D. Gray, who will step down at the end of March, ensuring continuity and stability in financial management.
- Background: Payantas has been with Ingredion since 2012, holding various key positions, most recently as Vice President of Finance for Global Texture & Healthful Solutions since November 2025, demonstrating his extensive experience and capability within the company.
- Financial Outlook: Ingredion anticipates earnings per share in the range of $11 to $11.80 for 2026, indicating confidence in its growth initiatives related to clean label and protein fortification, reflecting a positive outlook on future market demand.
- Strategic Transformation: This executive change aligns with the company's ongoing transformation strategy aimed at enhancing its competitiveness in high-yield and defensive investment sectors, further driving long-term growth.
See More
AI Sparks Potential Blue-Collar Renaissance Amid Job Disruption Fears
- Blue-Collar Employment Revival: Oppenheimer analysts suggest that while AI may rapidly displace white-collar jobs, it could simultaneously drive demand for blue-collar roles, particularly in manufacturing, with employment projected to remain below pre-pandemic levels by 2026.
- Investment Theme Analysis: Oppenheimer outlined five investable themes, including the physical-to-digital connection, emphasizing the value of sensors and data pipelines, with companies in this space expected to benefit from automation trends, including Aeva Technologies and Tesla.
- Automation Tools Opportunity: The analysts identified automation tools that can reskill transitioning workforces, recommending companies like Caterpillar and Rockwell Automation, which enhance worksite experiences through task automation and AI agents.
- Autonomous Systems Development: Oppenheimer also highlighted companies supporting autonomous physical systems, such as Mobileye Global and Aurora Innovation, noting that as fully autonomous solutions are commercialized, human roles will still be essential for remote monitoring and maintenance to ensure safety and problem resolution.
See More
Ingredion Q1 Earnings Miss Expectations with EPS Guidance Adjusted
- Earnings Performance: Ingredion's Q1 non-GAAP EPS of $2.34 missed expectations by $0.13, indicating pressure on profitability that could undermine investor confidence and stock performance.
- Revenue Decline: The company reported revenue of $1.79 billion, a slight year-over-year decrease of 1.1%, which, while in line with expectations, suggests a lack of sales growth that may impact future market competitiveness.
- Guidance Adjustment: Ingredion adjusted its full-year EPS guidance to a range of $9.60 to $10.30, with adjusted EPS guidance set at $10.45 to $11.15, falling short of the $11.33 consensus, reflecting a cautious outlook on future performance.
- Stock Reaction: Following the earnings report, Ingredion's shares fell by 4%, indicating market concerns regarding the company's performance and future prospects, which may lead investors to reassess their investment strategies.
See More
Ingredion Set to Announce Q1 Earnings on May 5
- Earnings Announcement Date: Ingredion (INGR) is scheduled to announce its Q1 2023 earnings on May 5 before market open, with consensus EPS estimate at $2.47, reflecting a 16.8% year-over-year decline, which could negatively impact investor sentiment.
- Revenue Decline Expected: The anticipated revenue for Q1 is $1.79 billion, down 1.1% year-over-year, indicating challenges the company faces in the current economic environment, potentially affecting its future market performance.
- Historical Performance Review: Over the past two years, Ingredion has only beaten EPS estimates 75% of the time and has never exceeded revenue estimates, highlighting ongoing pressures on the company's profitability and revenue growth.
- Management Change: Jason Payant was appointed interim CFO effective April 1, a change that may influence the company's financial strategy and investor confidence during a critical period of transformation and growth.
See More
Sensient Technologies Set for Growth as Shift to Natural Dyes Accelerates
- Market Transformation Opportunity: According to UBS, U.S. food producers and grocers are transitioning from synthetic dyes to natural colorants, which is expected to create significant growth opportunities for Sensient Technologies, with analyst Joshua Spector noting this shift will act as a positive catalyst for the company's stock.
- Price Target Increase: UBS initiated coverage with a buy rating on Sensient, setting a price target of $115, implying a 33% upside from Tuesday's close, reflecting confidence in the company's future growth potential.
- Sales Growth Expectations: By 2030, Sensient's color group sales are projected to increase by over 200% due to the growing adoption of natural food colorings, significantly enhancing the company's market share and profitability, particularly in North America.
- Analyst Consensus: Among the three analysts covering Sensient, two have assigned strong buy or buy ratings, indicating a general optimism about the company's future performance, despite its shares having fallen nearly 3% year-to-date.
See More
Jim Cramer's Trust Increases Stake in Cardinal Health
- Increased Stake: Jim Cramer's Charitable Trust purchased 25 shares of Cardinal Health at approximately $210, raising its total holdings to 475 shares and increasing its portfolio weighting from 2.5% to 2.6%, reflecting confidence in the company.
- Market Reaction: Cardinal Health's stock has pulled back about 9% since the onset of the conflict with Iran; however, the company is expected to see earnings per share grow approximately 25% in the current fiscal year, indicating strong profitability amid market volatility.
- Product Growth: Sales of GLP-1 medications have provided a significant tailwind to Cardinal's Pharmaceutical and Specialty Solutions business, contributing 6 percentage points to revenue growth in the most recent quarter, further solidifying its market position.
- Board Changes: The sudden retirement of Chairman Gregory Kenny, replaced by current director Patricia Hemingway Hall, may unsettle investors; however, the company clarified that this decision was not related to operational disagreements and maintains confidence in its future financial outlook.
See More
Ingredion Appoints Interim CFO Jason Payantas Effective April 2026
- Executive Change: Ingredion announced that Jason Payantas will serve as interim Chief Financial Officer starting April 1, 2026, succeeding James D. Gray, who will step down at the end of March, ensuring continuity and stability in financial management.
- Background: Payantas has been with Ingredion since 2012, holding various key positions, most recently as Vice President of Finance for Global Texture & Healthful Solutions since November 2025, demonstrating his extensive experience and capability within the company.
- Financial Outlook: Ingredion anticipates earnings per share in the range of $11 to $11.80 for 2026, indicating confidence in its growth initiatives related to clean label and protein fortification, reflecting a positive outlook on future market demand.
- Strategic Transformation: This executive change aligns with the company's ongoing transformation strategy aimed at enhancing its competitiveness in high-yield and defensive investment sectors, further driving long-term growth.
See More
AI Sparks Potential Blue-Collar Renaissance Amid Job Disruption Fears
- Blue-Collar Employment Revival: Oppenheimer analysts suggest that while AI may rapidly displace white-collar jobs, it could simultaneously drive demand for blue-collar roles, particularly in manufacturing, with employment projected to remain below pre-pandemic levels by 2026.
- Investment Theme Analysis: Oppenheimer outlined five investable themes, including the physical-to-digital connection, emphasizing the value of sensors and data pipelines, with companies in this space expected to benefit from automation trends, including Aeva Technologies and Tesla.
- Automation Tools Opportunity: The analysts identified automation tools that can reskill transitioning workforces, recommending companies like Caterpillar and Rockwell Automation, which enhance worksite experiences through task automation and AI agents.
- Autonomous Systems Development: Oppenheimer also highlighted companies supporting autonomous physical systems, such as Mobileye Global and Aurora Innovation, noting that as fully autonomous solutions are commercialized, human roles will still be essential for remote monitoring and maintenance to ensure safety and problem resolution.
See More
